The Discounted Cash Flow (DCF) valuation of Capricor Therapeutics Inc (CAPR) is (14.96) USD. With the latest stock price at 7.68 USD, the upside of Capricor Therapeutics Inc based on DCF is -294.8%.
Based on the latest price of 7.68 USD and our DCF valuation, Capricor Therapeutics Inc (CAPR) is a sell. selling CAPR stocks now will result in a potential gain of 294.8%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.3% - 8.9% | 7.6% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (39.85) - (9.51) | (14.96) |
| Upside | -618.9% - -223.8% | -294.8% |